Letter to the Editor: Re: Aspartate aminotransferase-to-platelet ratio index (APRi) as biomarker for liver damage in biliary atresia (BA): a meta-analysis
Topic overview
This correspondence addresses methodological considerations in a meta-analysis evaluating APRi (aspartate aminotransferase-to-platelet ratio index) as a non-invasive biomarker for liver damage in biliary atresia. The author emphasizes the importance of methodological transparency and interpretive consistency when synthesizing heterogeneous clinical data in pediatric hepatology.
Key takeaways
- Methodological transparency is essential when synthesizing heterogeneous data in pediatric liver disease meta-analyses.
- APRi biomarker studies in biliary atresia require clear analytical boundaries to ensure valid clinical interpretation.
- Constructive peer dialogue strengthens the rigor and reproducibility of hepatobiliary research in children.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Letter to the Editor: Re: Aspartate aminotransferase-to-platelet ratio index (APRi) as biomarker for liver damage in biliary atresia (BA): a meta-analysis. GlobalCastMD Medical Library. 2025-07-04. https://dev.library.globalcastmd.com/article/10639?via_space=staycurrentmd
Comments